Wave life sciences announces topline results from phase 1b/2a focus-c9 study of wve-004 for c9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated

WVE Ratings Summary

WVE Quant Ranking